Meizhu Chen
Family · Brooklyn, NYNPI 1770152969
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,418 of the $4,967 with a category attached, or 88.9%. It is spread thinly across 33 manufacturers, the largest accounting for just 10.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,356, 8.3 times the $284 reported in 2022. Among family clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 134 payments — averaging $37.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$510
- Johnson & Johnson$498
- Daiichi Sankyo Inc.$476
- Merck$417
- Exelixis Inc.$385
- Incyte Corporation$293
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,41889%
- Education$54911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 10 | $510 |
| Johnson & Johnson | 13 | $498 |
| Daiichi Sankyo Inc. | 6 | $476 |
| Merck | 13 | $417 |
| Exelixis Inc. | 3 | $385 |
| Incyte Corporation | 10 | $293 |
| Esperion Therapeutics, Inc. | 2 | $284 |
| Eisai Inc. | 10 | $241 |
| Stemline Therapeutics Inc. | 5 | $220 |
| Astellas Pharma US Inc | 8 | $189 |
| Taiho Oncology, Inc. | 7 | $163 |
| Gilead | 7 | $152 |
| Coherus Oncology, Inc. | 1 | $148 |
| Lilly USA, LLC | 5 | $116 |
| Seagen Inc. | 1 | $100 |
| Novartis | 3 | $85 |
| Puma Biotechnology, Inc. | 4 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $78 |
| Pfizer | 3 | $67 |
| Blueprint Medicines Corporation | 2 | $65 |
| Karyopharm Therapeutics Inc. | 2 | $60 |
| Mirati Therapeutics, Inc. | 3 | $57 |
| Bristol Myers Squibb | 2 | $51 |
| Genmab U.S., Inc. | 2 | $46 |
| Tactile Systems Technology Inc | 1 | $28 |
| Bayer | 1 | $28 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Exact Sciences | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Syndax Pharmaceuticals, Inc. | 1 | $18 |
| Tersera Therapeutics LLC | 1 | $17 |
| Amgen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,967 in reported general payments places this provider in the 90th percentile of 8,883 family providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 57 | $946,855 |
| XtandiEnzalutamide | 17 | $235,775 |
| Diclofenac Epolamine | 80 | $59,519 |
| EliquisApixaban | 126 | $48,061 |
| Abiraterone Acetate | 22 | $47,527 |
| JanumetSitagliptin Phos/Metformin Hcl | 43 | $26,982 |
| VascepaIcosapent Ethyl | 86 | $25,947 |
| JanuviaSitagliptin Phosphate | 49 | $20,934 |
| FarxigaDapagliflozin Propanediol | 29 | $16,171 |
| CreonLipase/Protease/Amylase | 12 | $10,894 |
| JardianceEmpagliflozin | 13 | $10,287 |
| XareltoRivaroxaban | 24 | $8,715 |
| Diclofenac Sodium | 23 | $7,785 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 13 | $7,496 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $6,278 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Farxiga | $510 | $963,02586 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $189 | $238,77028 claims |
| MerckJanumet, Januvia, Janumet Xr | $417 | $55,413105 claims |
| PfizerEliquis | $67 | $48,061126 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $18 | $16,56625 claims |
| Johnson & JohnsonXarelto | $498 | $8,71524 claims |
| NovartisEntresto | $85 | $5,88018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,883 family providers in New York.
Other family in Brooklyn
- Seida VelijaBrooklyn$62K
- Ofiong OkonBrooklyn$44K
- Irina FainbergBrooklyn$23K
- Susan WeissBrooklyn$22K
- Razan AlawadhiBrooklyn$21K
- Christina LaoBrooklyn$20K
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.